ConductScience.org, home

Paper41312948

Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.

Ahmed AA. Asian Pac J Cancer Prev, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway. Papers, record 41312948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41312948

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.
PubMed
Journal
Asian Pac J Cancer Prev
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ahmed AAAlyaa Aziz

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Uterine Cervical NeoplasmsMajor topic
Epithelial-Mesenchymal TransitionMajor topic
CiprofloxacinMajor topic
RivaroxabanMajor topic
Drug RepositioningMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Female
Drug Synergism
Molecular Docking Simulation
Cell Movement
Cell Proliferation
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127683123The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.Oncotarget2016https://conductscience.org/library/papers/27683123PubMed
238680005The Cytotoxic Effect of Ciprofloxacin Laetrile Combination on Esophageal Cancer Cell Line.Asian Pac J Cancer Prev2024https://conductscience.org/library/papers/38680005PubMed
339598770Unveiling the Anticancer Potential of a New Ciprofloxacin-Chalcone Hybrid as an Inhibitor of Topoisomerases I & II and Apoptotic Inducer.Molecules2024https://conductscience.org/library/papers/39598770PubMed
428112728Integrated genomic and molecular characterization of cervical cancer.Nature2017https://conductscience.org/library/papers/28112728PubMed
538403630Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis.World J Surg Oncol2024https://conductscience.org/library/papers/38403630PubMed
639551860Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.NPJ Precis Oncol2024https://conductscience.org/library/papers/39551860PubMed
738432579Effects of andiroba oil (Carapa guianensis aublet) on the immune system in inflammation and wound healing: A scoping review.J Ethnopharmacol2024https://conductscience.org/library/papers/38432579PubMed
836551965The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma.Biomedicines2022https://conductscience.org/library/papers/36551965PubMed
935839811Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.Lancet Glob Health2022https://conductscience.org/library/papers/35839811PubMed
10300442053D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.J Biomol Struct Dyn2019https://conductscience.org/library/papers/30044205PubMed
1132523090First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.Br J Cancer2020https://conductscience.org/library/papers/32523090PubMed
1233143025Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs.Mar Drugs2020https://conductscience.org/library/papers/33143025PubMed
1332397419Repurposing Cancer Drugs Batimastat and Marimastat to Inhibit the Activity of a Group I Metalloprotease from the Venom of the Western Diamondback Rattlesnake, Crotalus atrox.Toxins (Basel)2020https://conductscience.org/library/papers/32397419PubMed
1428954413Current Development Status of MEK Inhibitors.Molecules2017https://conductscience.org/library/papers/28954413PubMed
1535008569Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.Int J Mol Sci2021https://conductscience.org/library/papers/35008569PubMed
1640302088Scrutiny of the Co-Cytotoxic Impact of Metformin-Omeprazole on the Cervical Cancer Cell Line and Their Aptitude to Target Heat Shock 60.Asian Pac J Cancer Prev2025https://conductscience.org/library/papers/40302088PubMed
1736770806In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway.Molecules2023https://conductscience.org/library/papers/36770806PubMed
1837313143Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity.Heliyon2023https://conductscience.org/library/papers/37313143PubMed
1931791552
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol2020https://conductscience.org/library/papers/31791552PubMed
2032955176KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med2020https://conductscience.org/library/papers/32955176PubMed

See all 60 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TNKS8658PubTator's text mininghttps://conductscience.org/library/genes/8658

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41312948

GET https://conductscience.org/api/papers/v1/41312948/references?page=2